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Abstract 
 
The gut-derived hormone peptide YY (PYY) is most commonly known for its effect on satiety, 
decreasing food intake and body weight in animals and humans. However, PYY is also 
involved in a wide range of digestive functions including regulating insulin secretion and 
glucose homeostasis. Over the last few years, there have been several interesting clinical 
and animal studies investigating the role of PYY in glucose homeostasis. This review aims to 
present an updated summary of findings over the last few decades highlighting the role of 
PYY in regulating insulin output and insulin sensitivity, and the potential mechanisms 
involved. 	  
1. Introduction 
 
Peptide YY (PYY) was originally named in light of two tyrosine residues at the N- and C-
terminus of the protein [46]. PYY belongs to a family of peptides that includes neuropeptide Y 
(NPY) and pancreatic polypeptide (PP). These peptides are comprised of 36 amino acids and 
share extensive sequence homology [43]. PYY is expressed in both neurons and endocrine 
cells, notably endocrine L cells in the colon epithelium, whereas NPY and PP are 
preferentially expressed in neurons and endocrine cells, respectively. These peptides have 
various functions based on their receptor binding affinity to G-coupled protein Y receptors 
(Y1, Y2, Y4, Y5, Y6) that are widely expressed on different cells and organs. 
 There are two endogenous forms of PYY: PYY1-36 and PYY3-36. PYY3-36 is 
produced by the removal of two N terminal amino acids from the full-length form via dipeptidyl 
peptidase-IV (DPPIV) [43]. DPPIV is a cell surface enzyme ubiquitously expressed on 
endothelial and epithelial cells [35]. This enzyme most likely cleaves PYY3-36 from the full-
length form as it is secreted from L cells in the colon. In removing the two N terminal amino 
acids, DPPIV changes the receptor specificity of PYY3-36 [35]. In contrast to PYY1-36, which 
binds to the Y1, Y2 and Y5 receptor and with lesser affinity to the Y4 receptor, PYY3-36 
predominantly binds to the Y2 and Y5 receptor [9]. 
 
1.1. Distribution of PYY 
PYY is mainly produced by endocrine L cells of the colon and rectum and appears to be the 
earliest hormone released by colonic endocrine cells, suggesting that this hormone is 
important in the development of the gastrointestinal tract [49]. PYY is also produced by 
endocrine cells of the lower intestine, stomach and pancreas and is present in neurons of the 
central nervous system (hypothalamus, pons, medulla, brainstem and spinal cord) and 
peripheral nervous system (enteric neurons) [16] and [41]. 
 Within the pancreas, PYY is primarily co-expressed with glucagon in alpha cells of 
the islets of Langerhans, but is also found in pancreatic polypeptide-expressing islet cells as 
well as the exocrine pancreas [12]. The expression of PYY in early pancreatic islet cell 
precursors, particularly in the lineage-specific glucagon producing alpha cells, suggests that 
PYY may have a vital role in the differentiation, growth and development of the pancreas [16]. 
Considering that PYY is co-expressed in all islet cell types, albeit in lower quantities than in 
alpha cells, it appears that that all islet cell types are derived from a common PYY-expressing 
progenitor cell [48]. Interestingly, pancreatic alpha cells and intestinal cells that express PYY 
also co-express glucagon or glucagon-like peptides (GLP-1 and GLP-II), respectively [16]. 
 
1.2. Factors influencing the release of PYY 
In humans, PYY3-36 is the main form produced postprandially, contributing to approximately 
63% of circulating PYY in the fed state and only 37% in the fasted state [18]. PYY levels 
increase within 15 min of ingesting a meal, peak at approximately 60 min after ingestion and 
remain elevated for up to 6 h [1]. The initial rise in circulating PYY levels occurs before 
nutrients have reached the L cells of the colon, suggesting that an indirect neural and/or 
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hormonal response regulates the immediate release of PYY after ingestion of a meal [43]. 
The sustained production of PYY after a meal appears to be a direct effect of intraluminal 
contents acting on the endocrine L cells of the colon [40]. Interestingly, dietary fat is the most 
potent stimulant of PYY release [3]. 
 
1.3. Functions of PYY 
PYY regulates a broad range of gut functions that are mainly inhibitory. These include 
inhibiting glucose-stimulated insulin secretion [12], inhibiting gastric secretion and emptying 
[3], decreasing gastrointestinal motility [29], reducing gallbladder emptying [23], inhibiting 
pancreatic and intestinal secretion [46], promoting vasoconstriction to the gastrointestinal 
tract and pancreas [30] and [46] and enhancing salt and water absorption in the colon [39]. All 
of these PYY-mediated effects are induced via actions on the brainstem, and could affect 
digestion, absorption, satiety and energy balance [37] and [40]. Indeed, it has been shown 
that both forms of PYY reduce food intake when peripherally administered [15]. Other 
functions of PYY include inhibiting lipolysis [14] and stimulating the proliferation of the 
gastrointestinal mucosa [28]. More recently, it has been demonstrated that PYY exhibits a 
mitogenic effect on pancreatic acinar and ductal cells in vitro [26]. 
 
2. Effect of PYY1-36 on glucose homeostasis 
Initial studies revealed that PYY administered intravenously to mice has no effect on basal 
plasma levels of insulin, glucagon or glucose [12]. However, in the dog, it was shown that 
PYY administered intravenously at postprandial concentrations inhibits basal insulin secretion 
[19] and [21]. In contrast, there have been more consistent findings to confirm that PYY has 
an important role in glucose-stimulated rather than basal insulin secretion. Intravenously 
administered PYY inhibits glucose-stimulated insulin secretion as well as carbachol- and 
arginine-induced glucagon secretion in mice [12] and [45]. In vitro studies also demonstrate 
that PYY dose-dependently inhibits glucose-stimulated but not basal insulin secretion [38]. 
This is supported by work on isolated mouse islets where PYY antiserum potentiates glucose-
induced insulin secretion in culture [25]. Indeed, studies using perfused islets isolated from 
rats suggest that this is a direct action of PYY on islets [7]. 
 Studies from our laboratory suggest that PYY has an important regulatory role in 
insulin secretion in vivo. PYY knockout mice generated by us that do not produce PYY1-36 or 
PYY3-36 are equally glucose tolerant as control mice. However, they have significantly higher 
insulin levels for the duration of a glucose tolerance test [11]. Islets of Langerhans from PYY 
knockout mice were found to hyper-secrete insulin in response to high glucose concentrations 
[10]. Together, these data suggest that PYY importantly modulates glucose-stimulated insulin 
secretion from the islets of Langerhans. 
 
2.1. Effect of PYY3-36 on glucose homeostasis 
Recent studies have investigated whether PYY3-36, like PYY1-36, also has a role in 
regulating glucose homeostasis in vivo, in light of the new findings that PYY3-36 reduces food 
intake. In a study by Pittner et al. [42], a single intraperitoneal injection of PYY3-36 
administered to fasted ob/ob and db/db mice did not affect plasma glucose concentrations. 
Furthermore, a 4-week infusion of PYY3-36 by osmotic pump to ob/ob mice and fa/fa rats did 
not influence fasting plasma glucose levels [42]. In contrast, circulating HbA1c and 
fructosamine levels are lowered in genetically obese rodents and in diet-induced obese mice 
also given a 4-week infusion of PYY3-36 by osmotic pump, consistent with a possible 
hyperglycemic-lowering effect of PYY3-36 [36]. However, the effect of PYY3-36 on fasting 
insulin and glucose-stimulated insulin levels were not reported in either of these two studies. 
Separate experiments have also shown that PYY3-36 had no effect on glucose-stimulated 
insulin secretion or arginine-stimulated glucagon secretion in anesthetized Sprague–Dawley 
rats [8]. 
 It is important to address the fact that PYY3-36 is predominantly produced after a 
meal and may therefore be less potent in affecting fasting glucose and insulin levels when 
compared to PYY1-36. Interestingly, one study has compared these two forms of PYY in 
inhibiting 2-deoxy-d-glucose (2-DG)-stimulated insulin release, demonstrating that PYY3-36, 
the main form produced postprandially, inhibits d-glucose-stimulated insulin release, a 
glucose analogue and vagal stimulant of insulin release, albeit to a lesser degree than PYY1-
36 [52]. It may be worthwhile to explore and compare the effects of PYY1-36 or PYY3-36 or 
both forms together on basal and glucose-stimulated insulin secretion in vivo and in vitro, and 
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in acute and long-term studies to determine how these peptides function in fasting and 
postprandial conditions and whether these peptides have a synergistic action. 
 
2.2. Mechanisms for PYY-mediated inhibition of insulin secretion 
The mechanism by which PYY inhibits insulin secretion is still unclear. However, several 
studies have led to an understanding that PYY acts on Y1 receptors to influence insulin 
secretion. A study in conscious dogs suggests that Y2 and Y5 receptors are not involved in 
the inhibitory effect of PYY on 2DG-induced insulin secretion, and that the effect is likely to be 
mediated by Y1 receptors [52]. This is because PYY3-36, a selective Y2 and Y5 agonist, was 
less potent than PYY1-36, an agonist for all known Y receptors, in inhibiting insulin secretion. 
Moreover, the Y1 receptor requires the amino acid terminal of PYY for full biological activity 
[52]. The finding that PYY3-36 had no effect on glucose-stimulated insulin secretion in rats 
also suggests that insulin secretion is not mediated by Y2 or Y5 receptors [8]. One study has 
suggested that PYY inhibits insulin secretion by inhibiting the accumulation and action of 
cyclic AMP [38]. However, as adenylate cyclase inhibition is a feature of all Y receptor 
subtypes, it was not determined which Y receptor subtype was involved in the PYY-mediated 
inhibition of insulin secretion [38]. 
 It is likely that PYY acts directly on Y1 receptors in the pancreas to inhibit insulin 
secretion. Of all the known Y receptors, only the Y1 receptor subtype has been detected on 
pancreatic islets [13]. Within the islet of Langerhans, it has been demonstrated that these Y1 
receptors are found on beta cells that produce insulin [54] and delta cells that produce 
somatostatin, a hormone that potently inhibits insulin and glucagon secretion [33]. However, 
the possible mechanisms by which PYY secreted by alpha cells acts via the Y1 receptor on 
beta or D cells to influence insulin secretion requires further investigation. 
 PYY may also act on and influence other cells in pancreatic islets to inhibit insulin 
release by beta cells. Indeed, it has been shown that PYY inhibits arginine-induced secretion 
of glucagon in anesthetized rats [33]. Moreover, PYY decreases the insulin-stimulating effect 
of glucagon in perfused isolated mouse islets at glucose concentrations where PYY alone 
does not affect insulin secretion [25]. This suggests that PYY may indirectly attenuate the 
stimulatory effect of glucagon on insulin secretion [25]. Considering PYY and glucagon are 
co-localized in the secretory granules of islet alpha cells, it is possible that PYY acts as a 
paracrine regulator of insulin secretion [38]. However, it is still unclear whether PYY is co-
released with glucagon [25]. Another study from the same laboratory also revealed that PYY 
inhibits gastric inhibitory polypeptide (GIP)-stimulated insulin secretion in dogs [21]. Both of 
these studies imply that PYY may be part of an integral negative feedback loop, which 
regulates insulin secretion. 
 PYY may also exert its effects on the central nervous system to inhibit insulin 
secretion. It is likely that PYY binds to the Y1 and Y2 receptors located in the brainstem to 
modulate vagal output and influence digestive functions that include regulating insulin 
secretion [22] and [31]. Studies have demonstrated that PYY inhibits neurally-stimulated 
insulin release mediated by 2-DG in dogs and mice [19] and [20]. In particular, it was shown 
that PYY blocks β-adrenergic-stimulated insulin secretion in dogs [19]. However, PYY also 
inhibits neuropeptide-stimulated insulin release mediated by gastrin-releasing peptide (GRP) 
and tetragastrin (G4) [20]. 
 
2.3. Effect of PYY3-36 on insulin sensitivity 
Although it appears that PYY3-36 has less of a role on basal and glucose-stimulated insulin 
secretion, recent studies suggest a role for PYY3-36 in regulating insulin sensitivity. From the 
same study by Pittner et al. [42], a 4-week infusion of PYY3-36 by osmotic pump to diabetic 
fatty Zucker rats not only improves glycemic indices of HbA1c and fructosamine, but also 
results in a trend to improved insulin sensitivity during hyperinsulinemic–euglycemic clamps 
[42]. A later study also showed that an intravenous infusion of PYY3-36 for several hours 
under hyperinsulinemic–euglycemic clamp conditions in diet-induced insulin resistant mice 
enhanced insulin sensitivity and improved glucose disposal [50]. However, PYY3-36 had no 
affect under either basal or hyperinsulinemic conditions to reduce endogenous glucose 
production [42]. 
 Together, these two studies highlight that endogenous PYY3-36 may influence insulin 
sensitivity and glucose uptake. A possible mechanism by which PYY3-36 could influence 
insulin sensitivity is via the hypothalamic Y2 receptor. This is likely, considering previous 
reports have demonstrated that PYY3-36 acts on the Y2 receptor to inhibit NPY neurons and 
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activate proopiomelanocortin (POMC) neurons in the hypothalamus [6]. Moreover, NPY over-
expression in the hypothalamus results in obesity and insulin resistance in rodents 
[32] and [53], whereas activation of melanocortin receptors 3 and 4 enhance insulin sensitivity 
and inhibition of these receptors diminish insulin sensitivity [32] and [53]. However, the 
downstream pathways by which PYY3-36 leads to changes in glucose uptake by muscle and 
adipose tissue are not well characterized [50]. It is still to be determined whether PYY1-36 
has a role in regulating insulin sensitivity. 
 
3. Clinical studies 
 
PYY was not found to inhibit basal insulin secretion in humans after acute intravenous 
administration [2]. A more in depth study has also revealed that PYY administered acutely 
does not influence glucose-stimulated insulin secretion or the glucose elimination rate in a 
population of healthy female subjects [4]. There has been only one study investigating 
circulating PYY profiles after an oral glucose tolerance test in obese and lean people. This 
study showed that the PYY was comparable between lean and obese people, despite the fact 
that the obese people were more insulin resistant and produced significantly more insulin in 
response to glucose [27]. Another study found no correlation between circulating PYY or 
insulin levels in normal, obese and anorexic subjects [44].  
 There have also been several studies investigating the effect of PYY3-36 on glucose 
homeostasis in humans. One study showed that PYY3-36 infusion did not affect circulating 
insulin levels in either obese or lean subjects [5]. It has also been reported that fasting PYY3-
36 levels are significantly higher in type 2 diabetic subjects than controls, although this 
difference did not correlate to insulin or glucose levels [17]. Also, this study demonstrated that 
postprandial PYY levels were blunted when compared to controls [17]. 
 Although these studies suggest that PYY1-36 or PYY3-36 do not have a role in 
glucose homeostasis, it is important to highlight that PYY levels were measured in obese 
people that already have high fasting insulin [5], in diabetic subjects that were already insulin 
resistant [17] or in anorexic subjects who had an eating disorder and were likely to have an 
altered PYY response in addition to having decreased baseline insulin levels [44]. Indeed it is 
feasible that these obese, diabetic and anorexic subjects may have decreased sensitivity to 
PYY1-36 and PYY3-36, which normally function to influence glucose-stimulated insulin 
secretion or insulin sensitivity, respectively. There have not been any studies to date 
investigating the effects of PYY3-36 on insulin sensitivity in humans. However, more recent 
findings demonstrating that there is a modest association between the Arg72Thr mutation in 
the PYY gene and a decrease in glucose tolerance and lower glucose-stimulated insulin 
release in type 2 diabetes [47] highlights that the effect of PYY and glucose homeostasis is 
worth investigating further. 
 In contrast to previous studies investigating PYY levels in people with metabolic 
disorders, we recently investigated PYY levels in a group of females who were first-degree 
relatives of people with type 2 diabetes [10]. Our aims were to determine whether PYY 
deficiencies play a causative role in the development of obesity and type 2 diabetes. We 
found that women with a genetic propensity to type 2 diabetes and the development of 
excess adiposity had significantly lower fasting serum PYY levels than controls without any 
family history of type 2 diabetes. Fasting serum PYY levels were positively correlated with 
insulin sensitivity, and negatively correlated with fasting serum adiponectin levels, which 
predicts both adiposity and insulin sensitivity [24] and [51]. There was also a negative 
correlation between fasting serum PYY levels and HOMA-B, an estimation of insulin secretion 
using the homeostasis model assessment, which approximates the steady state beta cell 
function for the duration of the euglycaemic–hyperinsulinemic clamp, using the fasting serum 
glucose and insulin levels [34]. These data together with our in vitro work suggests that low 
circulating levels of PYY could contribute to the development of insulin hypersecretion and 
insulin resistance. Moreover, low PYY levels may predispose to the subsequent development 
of excess adiposity and type 2 diabetes that occurs with high frequency in people with a 
family history of type 2 diabetes. 
 Currently, DPPIV inhibitors are being used in clinical trials for the treatment of type 2 
diabetes. This is because DPPIV is the major enzyme that degrades incretins such as 
glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), 
which are important in reducing glucose levels and stimulating insulin secretion [35]. 
However, DPPIV inhibitors would conceivably block the production of PYY3-36. It has not 
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been established whether DPPIV inhibitors promote the action of PYY1-36 to influence insulin 
secretion. Moreover, it is unclear whether DPPIV inhibitors attenuate the effect of PYY3-36 to 
enhance insulin sensitivity. Indeed, DPPIV is also required for the anorectic effect of PYY3-36 
and therefore DPPIV inhibitors may down regulate the function of incretins and negatively 
influence food intake in type 2 diabetic subjects. Nonetheless, it is important to determine 
whether these incretins, which are produced by the same endocrine L cells that produce PYY, 
co-regulate insulin secretion or food intake. 
 
4. Conclusions 
 
From the studies performed so far, it appears that PYY1-36 has a more potent role in 
inhibiting glucose-stimulated insulin secretion than PYY3-36, whereas PYY3-36 acts to 
improve insulin sensitivity. Future experiments need to address whether PYY1-36 affects 
insulin sensitivity as well as to clarify the combined effect of both PYY1-36 and PYY3-36 in 
influencing glucose-stimulated insulin secretion. It is likely that these two forms of PYY have 
different functions due to variations in receptor binding, and because they are differentially 
produced under fasting and postprandial conditions. To gain a better understanding into how 
these two forms of PYY influence glucose homeostasis, future experiments examining and 
comparing the short- and long-term effects of PYY1-36 and PYY3-36 on basal and glucose-
stimulated insulin secretion and insulin sensitivity in vivo and in vitro would be useful. This 
would also clarify whether these two forms of PYY have a synergistic or counter-regulatory 
function on insulin secretion and insulin sensitivity. These findings would contribute 
significantly towards understanding how these hormones might be altered in type 2 diabetes 
as well as understanding how DPPIV inhibitors may be acting on hormones other than 
incretins as a means for treating type 2 diabetes. 
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